Tai Yuan Shi

This research aims to develop and evaluate a teaching curriculum for tracheal intubation using CT-based three-dimensional imaging and 3D printing technologies. The goal is to help students learn anatomical knowledge, operational skills, and special handling techniques for both normal and difficult airways. The study compares this new curriculum with traditional teaching methods to assess their relative effectiveness. Participants are divided into two groups. Group A receives training with the newly developed 3D curriculum, while Group B is trained using traditional teaching, which involves instructors explaining the material via PowerPoint, highlighting key points, answering questions, and summarizing the content. Both groups cover the same teaching content. After training, students perform tracheal intubation on patients. During the study, researchers will evaluate the success rate of endotracheal intubation over approximately one year. Additional outcomes include complications related to intubation and student satisfaction and confidence scores. The study monitors the participants performance, satisfaction, and training outcomes to compare the two teaching methods effectively.

This research aims to better understand the relationship between cardiovascular disease CVD and chronic kidney disease CKD, especially in people who have type 2 diabetes mellitus T2DM. Since CKD is often missed or untreated in patients with CVD, the study focuses on identifying how common kidney protein loss albuminuria is in these patients. The findings will help improve prevention and treatment strategies for those at high risk, aiming to reduce complications and slow kidney disease progression. The study will include about 3,000 adult patients with type 2 diabetes and cardiovascular disease who visit cardiology departments in 30 hospitals across China. Researchers will assess protein levels in the urine, known as albuminuria, to see how frequently it occurs among these patients. The participants will be recruited over six months, with evaluations occurring on the day they enroll in the study. Participants will provide informed consent and undergo urine testing to measure albumin levels. Researchers will also collect information about factors influencing albuminuria and how patients are currently treated in cardiology departments. The main outcome measured is the prevalence of albuminuria, including its different levels, at enrollment. This observational study does not involve treatment but aims to collect important data to guide future care for patients with CVD and diabetes.

Researchers are developing a large, multi-center database platform called the brain-heart comorbidity platform to collect and analyze clinical, sample, and imaging data from patients newly diagnosed with various cardiovascular-related diseases. This observational study aims to integrate artificial intelligence into this platform to enhance research on brain-heart comorbid conditions, supported by the National Key Research and Development Program. The platform stores data on a physical server or virtual appliance at participating institutions, connected through a network that allows for data queries and aggregation across centers. The study collects information on patients diagnosed with diseases identified by specific ICD-10-CM codes, including ischemic heart diseases, cardiac arrest, atrial fibrillation, heart failure, aortic diseases, subarachnoid hemorrhage, intracerebral hemorrhage, cerebral infarction, vascular occlusions, cerebral aneurysm, moyamoya disease, and arteriovenous malformations. Participants undergo multi-disciplinary assessments and their data is carefully checked for quality through a standardized process that removes incomplete or inaccurate records. The main outcomes measured include rates of all-cause mortality and cardiovascular events at discharge and 30 days. This ongoing registry enables continuous data collection and evaluation to better understand outcomes for patients with brain-heart comorbidities.

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.